Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

NCT05611931 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

276

Enrollment

INDUSTRY

Sponsor class

Conditions

Endometrial Cancer

Interventions

DRUG: Selinexor
DRUG: Matching Placebo for selinexor

Sponsor

Karyopharm Therapeutics Inc

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]